Timur “Tim” Mitin, MD, PhD
Cancer and Blood Disorders
Radiation Oncology, Harvard Radiation Oncology Program, Boston, MA
American Board of Radiology/Radiation Oncology
Interest and Accomplishments:
Dr. Timur Mitin was born in Moscow, Russia, and came to the United States alone at the age of 16 to pursue his dreams of education. He received his BA cum laude in Chemistry and Biology at Cornell University and pursued his medical training in a combined MD/PhD program at Tufts University School of Medicine.
During his PhD training he studied cancer immunology and ultimately defended his thesis work on hormonal regulation of drug metabolism. Upon graduating from the medical school he went on to complete an internship year in internal medicine at Providence St. Vincent Hospital, and returned to Boston for his training in radiation oncology at Harvard Radiation Oncology Program, where he learned the arts and science of oncology from his mentors at Massachusetts General Hospital, Dana Farber Cancer Institute, Brigham and Women’s Hospital and Beth Israel Deaconess Medical Center.
After completing his residency program, he was invited to join the faculty of Harvard Medical School at the Massachusetts General Hospital, where he specialized in treatment of patients with genitourinary malignancies, using a combination of various modalities, including IMRT, IGRT, proton beam, brachytherapy and intraoperative radiotherapy. He was a first author of several review articles, as well as RTOG publications in the field of bladder preservation in patients with muscle-invasive bladder cancer.
He joined the medical staff at OHSU in 2014 and is now the Medical Director of the Tuality OHSU Cancer center. He is dedicated to bringing the cutting edge cancer treatment modalities to his patients.
- Weight Gain on Androgen Deprivation Therapy: Which Patients Are at Highest Risk?
- The role of systemic disease status in treatment outcomes for patients with newly diagnosed brain oligometastases and treated with stereotactic radiosurgery alone
- Management of lymph node-positive prostate cancer: the role of surgery and radiation therapy.
- Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase 2 trial.
- Trimodality therapy for bladder conservation in treatment of invasive bladder cancer.
- Urological cancer. The benefits of intermittent androgen-deprivation therapy.